EU AI Act for Healthcare: What Life Sciences Companies Need to Know before August 2026

Trending Articles
Latest Articles & News

EU AI Act for Healthcare: What Life Sciences Companies Need to Know before August 2026
EU AI Act 2026 healthcare enforcement requires immediate compliance to avoid penalties.

Navigating US Regulatory Requirements for AI-Powered Medical Devices: A Comprehensive Guide to FDA, HIPAA, and IRB Compliance
US AI medical device compliance requires navigating FDA, HIPAA, IRBs, and consent waivers strategically.

VERBIS Registration and Standard Contractual Clauses in Turkey: A Complete Guide for Life Sciences Companies Conducting Clinical Trials
Turkey's VERBIS registration and SCC requirements demand apostilles, tight deadlines, and experienced local guidance.

Strategic Guide: Clinical Trial Data Protection Compliance in Australia
Are your global data protocols robust enough to withstand an audit by the Office of the Australian Information Commissioner (OAIC)? For international sponsors, Australia represents a premier destination for clinical research, but it also presents a sophisticated "privacy-by-design" regulatory environment. This analysis details the mandatory framework required to align cross-border operations with local statutory obligations and HREC expectations.

Scientific Research and the GDPR: Challenges and Opportunities in Secondary Data Use
Turning clinical trial data into tomorrow’s breakthroughs isn’t just science—it’s law. We explore GDPR roadblocks, secondary use challenges, and the UK’s bold new approach.

Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
